Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerp, Belgium.
Bill & Melinda Gates Foundation, Seattle, WA, USA.
Future Microbiol. 2019 Oct;14:1321-1330. doi: 10.2217/fmb-2019-0196. Epub 2019 Sep 4.
Although global polio eradication is within reach, sustained eradication of all polioviruses requires cessation of oral poliovirus vaccine use to mitigate against vaccine-derived poliovirus circulation and vaccine-associated paralytic poliomyelitis. The first step in this direction was the WHO-recommended global withdrawal of live attenuated type 2 Sabin poliovirus from routine immunisation in May 2016, with future use restricted to outbreak response, and handling controlled by strict containment provisions (GAPIII). This creates unique challenges for development and testing of novel type 2 poliovirus vaccines. We describe the creation of a novel purpose-built containment facility, Poliopolis, to study new monovalent OPV2 vaccine candidates in healthy adult volunteers, which may be a model for future endeavors in vaccine development for emergency use.
虽然全球消灭脊髓灰质炎已指日可待，但要彻底消灭所有脊髓灰质炎病毒，就必须停止使用口服脊髓灰质炎疫苗，以避免疫苗衍生脊髓灰质炎病毒的传播和疫苗相关麻痹性脊髓灰质炎。为此，世卫组织建议 2016 年 5 月停止使用减毒活二型萨宾脊髓灰质炎病毒常规免疫接种，今后只限于应对疫情，且严格限制使用和管控（GAPIII）。这为新型二型脊髓灰质炎病毒疫苗的研发和测试带来了独特的挑战。我们描述了创建一个新的专用密闭设施 Poliopolis 的过程，该设施用于在健康成年志愿者中研究新型单价 OPV2 疫苗候选物，这可能为未来紧急用途疫苗研发的努力提供模型。
